CA3205839A1 - Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1 - Google Patents

Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1

Info

Publication number
CA3205839A1
CA3205839A1 CA3205839A CA3205839A CA3205839A1 CA 3205839 A1 CA3205839 A1 CA 3205839A1 CA 3205839 A CA3205839 A CA 3205839A CA 3205839 A CA3205839 A CA 3205839A CA 3205839 A1 CA3205839 A1 CA 3205839A1
Authority
CA
Canada
Prior art keywords
cancer
seq
antibody
tigit
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205839A
Other languages
English (en)
Inventor
Tong Zhang
Liu XUE
Qi Liu
Min Wei
Kang Li
Yunxia ZUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Switzerland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/CN2022/072869 external-priority patent/WO2022156726A1/fr
Publication of CA3205839A1 publication Critical patent/CA3205839A1/fr
Pending legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés de traitement du cancer ou d'augmentation, d'amélioration ou de stimulation d'une réponse immunitaire avec des anticorps qui se lient spécifiquement à un TIGIT (immunorécepteur de lymphocyte T avec des domaines Ig et ITIM, WUCAM ou Vstm3) et des fragments de liaison àl'antigène de ceux-ci en combinaison avec un anticorps anti-PD1.
CA3205839A 2021-01-21 2022-01-20 Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1 Pending CA3205839A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CN2021073083 2021-01-21
CNPCT/CN2021/073083 2021-01-21
CNPCT/CN2021/073308 2021-01-22
CN2021073308 2021-01-22
CN2021074141 2021-01-28
CNPCT/CN2021/074141 2021-01-28
CNPCT/CN2021/074644 2021-02-01
CN2021074644 2021-02-01
CN2021075310 2021-02-04
CNPCT/CN2021/075310 2021-02-04
CN2021091822 2021-05-05
CNPCT/CN2021/091822 2021-05-05
PCT/CN2022/072869 WO2022156726A1 (fr) 2021-01-21 2022-01-20 Procédés de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1

Publications (1)

Publication Number Publication Date
CA3205839A1 true CA3205839A1 (fr) 2022-07-28

Family

ID=87516481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3205839A Pending CA3205839A1 (fr) 2021-01-21 2022-01-20 Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1

Country Status (1)

Country Link
CA (1) CA3205839A1 (fr)

Similar Documents

Publication Publication Date Title
US20220153837A1 (en) Anti-tigit antibodies and their use as therapeutics and diagnostics
AU2017228055B2 (en) Antibodies specific to human poliovirus receptor (PVR)
CN112088167A (zh) 特异性针对人类连接蛋白4的抗体
US11807687B2 (en) Therapeutic compositions comprising anti-NRP2 antibodies
TW202016133A (zh) 抗ox40抗體和使用方法
WO2021098757A1 (fr) Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-tigit
US20230022859A1 (en) Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
US20230391883A1 (en) Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies
CA3205839A1 (fr) Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
WO2021098774A1 (fr) Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-pd1 ou anti-pdl1